secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2023-01-05T23:59:59+00:00
Accession:  0001193125-23-002405
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Seres Therapeutics appoints Claire Fraser, Ph.D. as Class II director and to Audit Committee
--------------------------------------------------------------------------------

- Board expanded to ten directors; Dr. Fraser appointed as Class II director and to Audit Committee.
- Standard non-employee director compensation: $45,000 annual retainer, $10,000 audit committee retainer.
- Initial option grant: 48,000 shares at $5.47 exercise price, vesting over four years or upon change in control.
- Entered into standard director and officer indemnification agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312523002405/0001193125-23-002405-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312523002405/d436852d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-002405

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer